Fundraising Fox

Talus Bio

YC S21

Seattle, US · Founded 2020 · Delaware corporation · 16 employees · 7 known investors

Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

AI & Machine LearningBiotechDeep TechHealthtechGenomicsDrug discoveryUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (S21)

Talus Bio was founded in 2020 by Alex Federation and Lindsay Pino.

AFAlex Federation
Alex Federationin𝕏FounderHe trained in medicinal chemistry, drug screening, and drug development under Jay Bradner at Harvard, and subsequently studied epigenomics and proteomics in Seattle before developing the company's gene regulator platform.
LPLindsay Pino
Lindsay Pinoin𝕏FounderLindsay Pino is Chief Technology Officer at Talus Bio, focusing on quantitative proteomics and scaling experimental approaches. He trained at the Broad Institute, University of Washington, and University of Pennsylvania.
CJChristopher Joyce
Christopher Joycein
MBMichelle Briscoe
Michelle Briscoein
WFWill Fondrie
Will Fondriein

Board

OAOmri Amirav-Drory
Omri Amirav-Droryin𝕏Board MemberGeneral Partner at NFX
JSJ. Seth Strattan
J. Seth StrattaninBoard directorGeneral Partner at Two Bear Capital

Investors · 7

Farvatn VentureBergen
Fifty YearsSan Francisco · $250K – $2M
FundersClubSan Francisco · $250K – $5M
NFXSan Francisco · $250K – $5Mvia Omri Amirav Drory · board
Two Bear CapitalWhitefish · $3M – $10M
Y CombinatorSan Francisco · $500K
BoxOne VenturesreportedMontréal · $500K

Reported raises · per SEC filings

Form D private placements

$9.4M disclosed across 1 round · 2024

▶$9.4MraisedAug 2024 · 11 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lindsay PinoExecutive Officer, Director
  • Michelle BriscoeExecutive Officer
  • Alex FederationExecutive Officer, Director, Promoter
  • Omri Amirav-DroryDirector
  • J. Seth StrattanDirector
Offering amount
$11.3M
Amount sold
$9.4M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Talus Bio went on to found or lead other companies.

Omri Amirav DroryDirectorFounded Renewal BioMilad AlucozaiBoard MemberFounded Revalia Bio, Inc.

Competitors · 1

by search overlap
Bioworld58 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Talus Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$398.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$307.5K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2022$455K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$333.9K
National Science FoundationPhase I2021$255.8K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Talus Bioscience: Drug Discovery Company Raises $11.2 Million (Seed+)pulse2.com · Aug 2024Talus Bio tacks on $11M to target hard-to-reach transcription factorsfiercebiotech.com · Aug 2024Talus Bioscience lands $4.3M in grant funding for drug discovery platform – GeekWiregeekwire.com · Aug 2023Talus Announces Close of Seed Funding Round and Hires New COO | Talus Bio - Biotechnology & Drug Discoverytalus.bio · Jun 2022Inspired by scientist CEOs, Seattle startup lands $9.75M to build up drug discovery platform – GeekWiregeekwire.com · Jun 2022To turn off disease-causing genes, Talus Bio wants to knock proteins off of DNA | FierceBiotechfiercebiotech.com · Aug 2021

Frequently asked questions

What does Talus Bio do?
Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Who founded Talus Bio?
Talus Bio was founded by Alex Federation, Lindsay Pino in 2020.
Who are Talus Bio's investors?
Talus Bio's investors include Farvatn Venture, Fifty Years, FundersClub, NFX, Two Bear Capital, Y Combinator, BoxOne Ventures.
How much funding has Talus Bio raised?
Talus Bio has disclosed $9.4M raised across 1 round.
Where is Talus Bio headquartered?
Talus Bio is headquartered in Seattle, US.